FDA Warns Against Use of Hydroxychloroquine in Non-Hospitalized COVID-19 Patients




WASHINGTON, D.C. — The Food and Drug Administration has cautioned consumers and health professionals against using hydroxychloroquine and chloroquine to treat non-hospitalized patients for COVID-19 or to prevent the virus, explaining that it can lead to life-threatening heart rhythm problems.

In an April 24 MedWatch Safety Alert, the agency noted that it authorized temporary use of the drugs “only in hospitalized patients with COVID-19 when clinical trials are not available, or participation is not feasible, through an Emergency Use Authorization (EUA).

Hydroxychloroquine and chloroquine are FDA-approved to treat or prevent malaria. Hydroxychloroquine is also FDA-approved to treat autoimmune conditions …






UPCOMING CONFERENCES




HarrisMartin's Webinar Series: Midwest Asbestos Litigation

December 02, 2020 - Haddonfield, NJ
HarrisMartin Webinar Series

MORE DETAILS



HarrisMartin’s Webinar Series: Surgical Stapler Litigation

January 14, 2021 - Haddonfield, NJ
HarrisMartin Webinar Series

MORE DETAILS